Rusfertide, a breakthrough therapy discovered for the treatment of patients with Polycythemia Vera (PV).
Rusfertide reduces the erythrocytosis in those patients who do not require further treatment for thrombocytosis and/or leucocytosis. Rusfertide which is a natural hormone mimeticis supposed to be the first non-cytoreductive therapeutic drug for PV.
Rusfertide in PV is considered to be a serious disease where the need for different and better treatment options is clear and pressing.
Studies have shown patients when treated with rusfertide, were able to eliminate therapeutic phlebotomies and maintain a target hematocrit level of less than 45 percent, reverse iron deficiency, and experience symptom improvements.
U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its lead investigational new drug candidate, rusfertide, for the treatment of patients with polycythemia vera (PV).